好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

The Association of HLA-DQB1*04 and DQB1*03 with Neuromyelitis Optica Spectrum Disorders: A Case-Control Study Considering Genetic Ancestry
Autoimmune Neurology
P7 - Poster Session 7 (5:00 PM-6:00 PM)
8-002

This study aims to establish the association between HLA class II alleles and the presence of Neuromyelitis Optica Spectrum Disorder (NMOSD) in a Colombian population


NMOSD is a demyelinating disease with a low prevalence in Latin America. International studies have identified associations between the risk of NMOSD and alleles of the human leukocyte antigen (HLA) class II complex. However, there are currently no studies in Colombia.

A multicenter case-control study was conducted with NMOSD patients diagnosed with the 2015 Wingerchuk criteria, recruited between 2020 and 2023 from Bogotá and Medellín, Colombia. Controls, without demyelinating or autoimmune diseases, were recruited from the same cities as were the cases. Blood samples from both groups were analyzed to identify HLA-DRB1 and HLA-DQB1 alleles using sequence-specific primer polymerase chain reaction (SSP-PCR). The mitochondrial hypervariable region 1 was amplified, and haplogroups were determined with HaploGrep software. Genomic ancestry was estimated by genotyping ancestry-informative markers. Logistic regression models assessed associations between HLA polymorphisms and NMOSD.


A total of 82 patients with NMOSD (mean age 43.8 ± 13.3 years; 83% females) and 164 controls (mean age 36.4 ± 11.5 years; 85% females) were enrolled. Mitochondrial haplogroup frequencies were similar between groups, indicating comparable genetic backgrounds. Ancestry analysis revealed distinct population structures. In multivariate logistic regression, the HLA-DQB1*04 allele was significantly associated with increased NMOSD risk (OR = 3.16, CI: 1.58-6.34, p < 0.0023), while the HLA-DQB1*03 allele was associated with a protective effect (OR = 0.23, CI: 0.12-0.46, p < 0.0023).


This study provides new insights into the genetic characterization of NMOSD in Colombia. Our findings suggest that HLA-DQB1*04 allele confers susceptibility to NMOSD, while DQB1*03 allele may exert a protective effect in our population. The notable disparities in African ancestry contribution between patients and controls underscore the importance of considering ethnic diversity in elucidating NMOSD susceptibility.


Authors/Disclosures
Jairo A. Gaitan Alfonso, MD (Fundación Santa Fe de Bogotá)
PRESENTER
Dr. Gaitan Alfonso has nothing to disclose.
Jaime Toro, MD, FAAN (Universidad El Bosque) Dr. Toro has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Watch Neurology .
Juliana Lago, PhD Dr. Lago has nothing to disclose.
Helena Groot (Universidad de los Andes) Helena Groot has nothing to disclose.
Daniela S. Rodriguez (Fundación Santafé) Ms. Rodriguez has nothing to disclose.
Carolina Restrepo-Aristizabal (Fundación Instituto Neurológico de Colombia) No disclosure on file
Cesar Franco Ruiz, MD Dr. Franco Ruiz has nothing to disclose.
MARIANA TORRES BUSTAMANTE, MD Dr. TORRES BUSTAMANTE has nothing to disclose.
Angie Montejo (Universidad de los Andes) No disclosure on file
Luisa Marquez (Universidad de los Andes) No disclosure on file
Diana Narvaez, PhD Dr. Narvaez has nothing to disclose.
Juan P. Rodriguez noriega, MD Dr. Rodriguez noriega has nothing to disclose.
David F. Cuellar Giraldo, Jr., MD (Universidad El Bosque) Dr. Cuellar Giraldo has nothing to disclose.
Habib Georges Moutran Barroso, MD (Universidad El Bosque) Dr. Moutran Barroso has nothing to disclose.
Fabian Cortés-Muñoz (Fundación Clínica Shaio) No disclosure on file
Daniel León Tramontini (Universidad de los Andes) Mr. León Tramontini has nothing to disclose.
Thomas F. Medina Ramirez (Edificio 53) Mr. Medina Ramirez has nothing to disclose.
Laura A. Serna Miss Serna has nothing to disclose.
Saul Reyes, MD (The Royal London Hospital) Dr. Reyes has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Dr. Reyes has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for BIIB. Dr. Reyes has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Merck. Dr. Reyes has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Biogen.